-SEC Filing
HC Wainwright & Co. Maintains Buy on Blueprint Medicines, Lowers Price Target to $80
HC Wainwright & Co. analyst Andrew Fein maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and lowers the price target from $100 to $80.
Related Posts
Foreign Buyers Desert US Treasury Bond Market As Supply Increases
China and Japan among the biggest foreign holders of U.S. bonds
Adobe’s AI Images Of Israel-Hamas Tensions Raise Alarm Over Media Truth
Adobe Stock is now offering for sale artificially created images depicting scenes from the Israel-Hamas conflict.
Why Addentax Shares Are Trading Higher Today
Addentax Group Corp. (NASDAQ: ATXG) formed a cooperation leading certain Games-as-a-Service firms to launch a project focusing on developing